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Abstract
Background: Glioblastoma is one of the deadliest forms of cancer, in part because of its highly invasive nature.
The tumor suppressor PTEN is frequently mutated in glioblastoma and is known to contribute to the invasive
phenotype. However the downstream events that promote invasion are not fully understood. PTEN loss leads to
activation of the atypical protein kinase C, PKCι. We have previously shown that PKCι is required for glioblastoma
cell invasion, primarily by enhancing cell motility. Here we have used time-lapse videomicroscopy to more
precisely define the role of PKCι in glioblastoma.
Results: Glioblastoma cells in which PKCι was either depleted by shRNA or inhibited pharmacologically were
unable to coordinate the formation of a single leading edge lamellipod. Instead, some cells generated multiple
small, short-lived protrusions while others generated a diffuse leading edge that formed around the entire
circumference of the cell. Confocal microscopy showed that this behavior was associated with altered behavior of
the cytoskeletal protein Lgl, which is known to be inactivated by PKCι phosphorylation. Lgl in control cells localized
to the lamellipod leading edge and did not associate with its binding partner non-muscle myosin II, consistent
with it being in an inactive state. In PKCι-depleted cells, Lgl was concentrated at multiple sites at the periphery of
the cell and remained in association with non-muscle myosin II. Videomicroscopy also identified a novel role for
PKCι in the cell cycle. Cells in which PKCι was either depleted by shRNA or inhibited pharmacologically entered
mitosis normally, but showed marked delays in completing mitosis.
Conclusions: PKCι promotes glioblastoma motility by coordinating the formation of a single leading edge
lamellipod and has a role in remodeling the cytoskeleton at the lamellipod leading edge, promoting the
dissociation of Lgl from non-muscle myosin II. In addition PKCι is required for the transition of glioblastoma cells
through mitosis. PKCι therefore has a role in both glioblastoma invasion and proliferation, two key aspects in the
malignant nature of this disease.
Introduction
Glioblastoma multiforme is a primary brain tumor with
a very poor prognosis. Despite the use of aggressive
therapeutic approaches combining surgery, radiation
and chemotherapy, the median survival time for patients
is only 12-14 months [1]. The highly invasive nature of
glioblastoma cells blurs tumor margins, making com-
plete surgical resection impossible. Additionally, it is
thought that invading cells may be more resistant to
radiation and chemotherapy [2]. Inhibition of cell inva-
sion may therefore be an effective strategy to improve
the treatment of glioblastoma.
Glioblastoma cell invasion requires that cells have
enhanced motility, along with an ability to degrade local
tissue barriers. The phosphoinositide 3-kinase (PI 3-
kinase) pathway is often constitutively active in glioblas-
toma as a result of mutations in PTEN, as well as muta-
tion and amplification of the epidermal growth factor
receptor [3]. These genetic alterations have been shown
to promote motility and invasion of glioblastoma cells
[4,5]. The PI 3-kinase pathway can activate multiple
downstream effectors including the atypical protein
kinase C family member PKCι [6,7]. The importance of
PKCι as a downstream effector in the PI 3-kinase path-
way is emphasized by the fact that PKCι can function as
an oncogene in several tumor types [8-10]. On this basis
it has been proposed that PKCι is a promising new tar-
get for cancer therapy [11].
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The activation of PKCι involves direct phosphorylation
by phosphoinositide-dependent kinase 1 and association
with Cdc42, a small GTPase that is extensively involved
in cell migration [6,7,12,13]. The atypical PKCs (PKCι
and PKCζ) have been shown to play a role in the estab-
lishment of multiple forms of cell polarity, including
asymmetric cell division and apical-basal polarity [14].
They form a conserved polarity complex with the scaf-
fold protein, Par-6, that links the atypical PKCs to other
proteins including Cdc42, Par-3 and Lgl [15].
We have shown previously that PKCι promotes moti-
lity and invasion of glioblastoma cells [16]. PKCι has
also been shown to promote the invasiveness of lung
cancer cells [17]. These studies have given insight into
the role of PKCι in cellular motility and invasion; how-
ever they have relied on static analyses of invasion, and
did not define precisely the role of PKCι in the dynamic
process of cancer cell migration. In this study, we have
investigated the role that PKCι plays in the regulation of
glioblastoma cell motility using time-lapse videomicro-
scopy. This showed that PKCι has a critical role in coor-
dinating lamellipod leading edge formation, an essential
step in glioblastoma invasion. Interestingly, videomicro-
scopy also revealed a role for PKCι in mitosis, indicating
an additional role for PKCι in the malignant phenotype
of glioblastoma.
Results
Downregulation of PKCι expression by shRNA
To stably deplete PKCι in glioblastoma cells, two unre-
lated PKCι-targeting shRNA expression plasmids
(pshPKCιA and pshPKCιB, sequences shown in Addi-
tional file 1, Figure S1A) were prepared and expressed
in human glioblastoma cell lines using retroviral trans-
duction, along with a GFP-targeting shRNA expression
plasmid which was used as a control. Stable pools of
transduced glioblastoma cells were isolated following
one week of selection in puromycin. In U87MG cells
expressing pshPKCιA, PKCι protein expression was
reduced by 60% (Figure 1A). pshPKCιB was less efficient
in repressing PKCι protein expression, reducing it by
only 25% and was not used in further experiments.
The motility and invasive properties of U87MG cells
transduced with pshPKCιA were assessed using Trans-
well chambers. To examine cell motility, control and
PKCι-depleted U87MG cells were seeded at the same
density in Transwell chambers and 22 h later the num-
ber of cells that crossed through the chamber were
counted. Stable depletion of PKCι resulted in a 65%
decrease in the number of cells that crossed through the
chamber (Figure 1B, top). To assess the effects on inva-
sion, control and PKCι-depleted U87MG cells were
seeded at equal densities into Transwell chambers that
were coated with a Matrigel layer. PKCι depletion also
caused a significant reduction (61%) in the number of
cells that were able to pass through the Matrigel-coated
chambers (Figure 1B, bottom). The fact that the differ-
ences in the number of cells that crossed through the
chamber in the presence or absence of Matrigel are
similar indicates that PKCι affects the invasion of glio-
blastoma cells primarily by promoting cell motility. This
is the same phenotype that we described previously with
transient transfection of two different RNA duplexes
targeting PKCι [16].
Time-lapse videomicroscopy of cell motility in U87MG
cells stably depleted of PKCι
To gain more insight into the mechanism by which
PKCι promotes glioblastoma cell motility, videomicro-
scopy was used. Control and PKCι depleted U87MG
cells were plated into a live cell imaging plate at a den-
sity of 103 cells to allow space for migration. Phase
contrast images of the cells were taken at 5 min inter-
vals for 20 h and compiled to generate a time-lapse
video. Quantitation of cell movement from videomi-
croscopy images confirmed the impairment in cell
motility in PKCι-depleted cells. Overall migration rates
were determined using data from three independent
time-lapse videos of each cell line. PKCι-depleted cells
had a 45% reduction in migration distance per minute
(0.14 μm/min compared to 0.26 μm/min in control
cells (Figure 1C)). Quantitation of lamellipod leading
edge formation from videomicroscopy showed that
cells depleted of PKCι had a markedly impaired ability
to form a single, dominant leading edge (Figure 1D).
Videomicroscopy showed that the loss of motility was
not due to a simple shutdown of cell movement, but
instead was due to a loss of coordination in this pro-
cess. Control cells show an initial extension of a single
leading process, followed by translocation of the
nucleus toward the lagging edge and finally retraction
of the trailing process (Figure 2 and Additional file 2,
Video 1). This results in the substantial movement of
cells before they change direction. In contrast, PKCι-
depleted cells primarily generate multiple short protru-
sions that emanate from all sides of the cell (Figure 2
and Additional file 3, Video 2); a smaller number of
cells show a flattened appearance which appears to be
due to an attempt to form a leading edge around the
entire circumference of the cell (Figure 2 and Addi-
tional file 3, Video 2). The consequence of this is that
there is little or no net movement of cells.
Inhibition of PKCι activity using an atypical PKC specific
pseudosubstrate peptide impairs cell motility
As a second method to assess the role of PKCι in glio-
blastoma cell motility, U87MG cells were treated with
an atypical PKC specific inhibitor (PS-I). This inhibitor
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is an atypical PKC pseudosubstrate that has been myr-
istoylated to make it cell permeable. Although it inhi-
bits both members of the atypical PKC family (ζ and
ι), we have shown previously that U87MG cells only
express PKCι, so that we can ascribe any effects of this
peptide specifically to inhibition of PKCι (see also
Additional file 1) [18]. Treatment of U87MG cells with
20 or 50 μM of PS-I caused a reduction in PKCι activ-
ity as assessed by phosphorylation at threonine 555
(Figure 3A). Quantification of the migration rate by
videomicroscopy showed that PS-I treatment caused a
47% reduction in migration distance per minute
(0.12 μm/min) compared to control cells (0.23 μm/
min; Figure 3B). Consistent with the shPKCιA expres-
sing cells, U87MG cells treated with PS-I showed an
impaired ability to generate a single dominant leading
edge (Figure 3C), with most cells forming multiple
small protrusions instead (Figure 3D and Additional
file 4, Video 3). A172 human glioblastoma cells in
which PKCι was either depleted with shRNA or inhib-
ited with PS-I also showed decreased motility when
analyzed by videomicroscopy, although the effect was
less marked as these cells are less motile than U87MG
cells (Additional file 5, Figure S2A).
Figure 1 Effects of stable PKCι depletion on cell motility. A. Western blot analysis and densitometry of PKCι expression in U87MG cells after
transduction with retroviral vectors expressing shGFP, shPKCιA and shPKCιB followed by puromycin selection. B. Cell motility in U87MG/shGFP
and U87MG/shPKCι cells was assessed using Transwell chambers without Matrigel (top) and invasion was assessed using Transwell chambers
with Matrigel (bottom). Data are from one of two independent experiments that gave similar results. C. Quantitation of motility from
videomicroscopy. Migration distance per minute (um/min) was measured using Ziess LSM image browser software. Bar graphs show the mean
+/- SD from three independent videomicroscopy experiments for each cell type (mean of 10 cells analyzed per experiment). D. Quantitation of
leading edge formation from videomicroscopy. Cells from three independent movies were analyzed for the formation of a single dominant
leading edge as described in Materials and Methods. Bar graphs show the mean +/- SD.
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Effects of PKCι on Lgl in migrating glioblastoma cells
Lgl is a cytoskeletal protein that has been shown to be a
direct substrate for phosphorylation by PKCι [19,20].
This phosphorylation inactivates Lgl, disrupting its abil-
ity to interact with cell membrane and non-muscle myo-
sin II [21]. We screened a number of antibodies to Lgl,
but did not find one that reliably detected endogenous
Lgl in glioblastoma cells without recognizing additional
species on Western blots. To overcome this problem,
we cloned human Lgl, added an amino-terminal Flag
epitope sequence, and transduced this into U87MG
cells. U87MG cells expressing Lgl cell showed similar
rates of proliferation compared to normal U87MG cells
(data not shown) and exhibited similar abilities to form
a coordinated leading edge based on microscopy assess-
ment (see Figure 4B). To assess Lgl phosphorylation by
PKCι in glioblastoma cells, Flag-tagged Lgl was immu-
noprecipitated from cells with and without PKCι deple-
tion. Immunoprecipitated Lgl was then analyzed by
Western blotting using antibody to PKC consensus
phosphorylation site. Lgl was constitutively phosphory-
lated in glioblastoma cells and this was reduced with
PKCι depletion (Figure 4A). PKCι therefore constitu-
tively inactivates Lgl in U87MG cells. We also attempted
to generate U87MG cells expressing a mutant, non-
phosphorylatable Lgl in which five hinge region serines
were mutated to alanine. However we were unable to
isolate populations expressing non-phosphorylatable Lgl
Figure 2 Examples of motility defects assessed using time-lapse videomicroscopy. Representative examples comparing cell motility in
control and PKCι-depleted cells. Still images from videomicroscopy are shown, with times indicated on the left. Representative full videos are
shown in Supplementary videos S1 (control) and S2 (PKCι-depleted).
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after retroviral transduction, suggesting that Lgl phos-
phorylation is required for normal growth of U87MG
cells.
In U87MG/Lgl cells that showed formation of a lamel-
lipod, Lgl was concentrated at the leading edge of the
lamellipod, in agreement with a previous study (Figure
4B, left panel)[20]. A detailed analysis by confocal
microscopy showed that Lgl did not colocalize with
non-muscle myosin IIA at the leading edge (Figure 5A).
Instead, Lgl was concentrated in a band in front of non-
muscle myosin IIA. This is in agreement with previous
data that non-muscle myosin IIA is excluded from the
lamellipod leading edge [22]. When flag-tagged Lgl-
expressing cells were depleted of PKCι, this pattern was
changed (Figure 4B). Cells showed the presence of mul-
tiple sites in which Lgl was concentrated and confocal
microscopy showed that Lgl colocalized with non-mus-
cle myosin II at these sites (Figure 5B). This is consis-
tent with a model in which Lgl is recruited to nascent
leading edges and is inactivated there by PKCι during
leading edge maturation.
Impaired cell division in U87MG cells depleted of PKCι
The effects of stable PKCι depletion on glioblastoma cell
proliferation was evaluated by counting cells using try-
pan blue exclusion to distinguish live from dead cells.
Viable cell numbers were determined 1, 2, 4 and 8 days
following plating of control and PKCι depleted cells at
Figure 3 Effects of PKCι pseudosubstrate inhibitor peptide on cell motility. A. U87MG cells were treated with 20 or 50 μM atypical PKC
pseudosubstrate peptide inhibitor (PSI) for 2 h. Whole cell lysates were then analyzed for levels of phosphorylated PKCι and total PKCι by
Western blotting. B. Migration distance per minute (um/min) was quantitated using Ziess LSM image browser software. Bar graphs show the
mean +/- SD from three independent videomicroscopy experiments each for control and PS-I treated U87MG cells (mean of 10 cells quantified
per experiment). C. Quantitation of leading edge formation from videomicroscopy. Cells from three independent movies were analyzed for the
formation of a single dominant leading edge. Bar graphs show the mean +/- SD. D. Representative examples comparing cell motility in control
cells and cells treated with 20 μM PS-I. Still images from videomicroscopy are shown, with times indicated on the left. A representative full video
is shown in Supplementary video S3.
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equal densities. Stable depletion of PKCι in both
U87MG and A172 human glioblastoma cells signifi-
cantly reduced growth rate compared to control cells
(Figure 6A). This was also seen in U87MG and A172
cells transiently transfected with two different RNA
duplexes targeting PKCι (Additional file 5, Figure S2B).
Time lapse videomicroscopy also confirmed that PKCι-
depleted cells had reduced proliferation and showed
that this was due, at least in part, to impaired mitosis
(Figure 6B and 6C and Additional file 3, Video 2). At
mitosis, U87MG cells undergo the rapid cell rounding
that has been described for many other cell types. They
then divide, flatten out and reinitiate cell movement.
This process takes from 150 to 300 min (Figure 6B). In
three independent videomicroscopy experiments, the
mean number of complete mitotic events observed over
20 h averaged 12 per field of view (Figure 6C inset
table). The total number of complete mitotic events
observed in the three control experiments was 35; these
all occurred within the 150-300 minute time frame and
were therefore considered “normal” mitotic events. In
PKCι-depleted U87MG cells, the mean number of com-
plete mitotic events observed over 20 h was 1 per field
of view for three independent experiments (starting cell
densities were similar for both cell types). Two factors
contributed to this reduction. The first is a reduction in
the number of cells that enter mitosis. The second fac-
tor is that the majority of cells that entered mitosis
remained rounded for > 500 min, with many failing to
complete mitosis within the 20 h timeframe of the
videos. In PKCι-depleted cells a total of 10 delayed
mitotic events were observed in three separate experi-
ments and only 3 normal events (Figure 6C inset table).
Similar to the observations in U87MG cells expressing
shPKCιA, treatment of U87MG cells with the PS-I
impaired cell proliferation (Figure 7A). Time-lapse
videomicroscopy showed that this was also a conse-
quence of impaired mitosis (Figure 7B, C and Additional
file 4, Video 3). The mean number of mitotic events
observed in three independent control experiments was
Figure 4 Effects of PKCι depletion on Lgl. A. U87MG cells expressing either empty vector (-) or vector expressing Flag-tagged Lgl (+) were
either mock-transfected (-) or transfected with an RNA duplex A targeting PKCι (+). Three days after transfection, cells were lysed and Flag-
tagged Lgl was immunoprecipitated. Immunoprecipitates were solubilized in Laemmli buffer, electrophoresed on SDS-PAGE gels and transferred
to membranes for analysis by Western blotting. Membranes were probed with antibodies to Flag epitope or phosphorylated PKC substrate, as
indicated. In the lane marked “nl”, the immunoprecipitation was performed with no lysate (buffer only). B. U87MG/Lgl cells were grown on
gelatin-coated coverslips and transfected with either scrambled duplex, RNA duplex A targeting PKCι or RNA duplex C targeting PKCι. Two days
later cells were fixed and immunocytochemistry for Flag-tagged Lgl (red) and non-muscle myosin IIA (green) was performed. Nuclei were
stained with DAPI.
Baldwin et al. Molecular Cancer 2010, 9:233
http://www.molecular-cancer.com/content/9/1/233
Page 6 of 13
9 over 17 h (Figure 7C inset table). The total number of
mitotic events observed in the three control experiments
was 27, all of which where characterized as normal
mitotic events based on timing (Figure 7C inset table).
U87MG cells treated with PS-I had a significant reduc-
tion in the number of mitotic events: a mean of 3 was
observed per 17 h video as compared to a mean of 9 in
control videos. A total of 5 delayed mitotic events and 7
normal events were observed in the three independent
live cell imaging analysis of PS-I treated U87MG cells
(Figure 7C inset table). Similar impairments in mitosis
were observed in videomicroscopy analyses of A172
cells in which PKCι was either depleted with shRNA or
inhibited with PS-I (Additional file 5, Figure S2C).
Discussion
We previously showed that PKCι promotes glioblastoma
cell invasion [16]. This was primarily due to the ability
of PKCι to promote cell motility and was linked to
repression of RhoB expression by PKCι. To extend these
findings, we have used time lapse videomicroscopy to
characterize the motility defects in PKCι-depleted glio-
blastoma cells. PKCι-depleted cells actively extended
multiple short protrusions, but have a markedly reduced
ability to form a single leading edge lamellipodium, an
essential feature of productive cell movement. This is
consistent with the established role of the atypical PKCs
in generating cell polarity in multiple contexts, including
apical/basolateral polarity and asymmetric cell division.
Our work is also consistent with the work of Etienne-
Manneville et al., which showed the presence of an aty-
pical PKC at the leading edge of migrating astrocytes in
association with Cdc42, although in their study this was
ascribed to PKCζ rather than PKCι [23].
The impaired motility of PKCι was associated with
altered behavior of the cytoskeletal protein Lgl. Lgl was
Figure 5 Confocal microscopy of Lgl and non-muscle myosin IIA in PKCι-depleted cells. A. Immunocytochemistry for Flag-tagged Lgl (red)
and non-muscle myosin IIA (green) was performed on U87MG cells transduced with Flag epitope-tagged Lgl cDNA. Nuclei were stained with
DAPI (blue). Three serial confocal optical sections are shown for a cell with a distinct leading edge, with the section closest to the substratum on
the left. B. Confocal images of U87MG cells transduced with Flag epitope-tagged Lgl cDNA that were either mock-transfected (left) or
transfected with an RNA duplex targeting PKCι (right). Flag-Lgl (red), non-muscle myosin IIA (green) and DAPI (blue) images are shown
separately and as a merged image in the bottom right quadrant.
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first described as a tumor suppressor in Drosophila, and
has been shown to be a direct substrate for PKCι in
both Drosophila and mammalian cells [19,20]. Phos-
phorylation of the central hinge region of Lgl inactivates
the protein with respect to its non-muscle myosin II
and membrane association functions [21,24]. Trans-
duced Lgl was concentrated at the leading edge of glio-
blastoma cells in agreement with a previous report [20]
and was constitutively phosphorylated in glioblastoma
cells. Lgl was not associated with non-muscle myosin
IIA, which was behind the lamellipod leading edge as
described previously [22]. PKCι depletion reduced Lgl
phosphorylation and changed its intracellular distribu-
tion such that it was concentrated at multiple sites
around the periphery of the cell, where it colocalized
with non-muscle myosin II. This is consistent with the
videomicroscopy evidence that these cells initiate multi-
ple uncoordinated attempts at leading edge formation.
Figure 8 shows a model for the role of PKCι in lamelli-
pod formation. PKCι is initially recruited to the plasma
membrane as a complex with the scaffolding protein
Par6 and Lgl [20]. At this point Lgl is associated with
non-muscle myosin II via its carboxy terminal domain
[21]. PKCι is then activated locally by PI 3-kinase and
Cdc42. This inactivates Lgl, disrupting its association
with non-muscle myosin II-containing actin filaments.
This then allows actin remodeling and forward spread-
ing of the lamellipod. In the absence of functional PKCι,
lamellipod formation is aborted due to failed uncoupling
of Lgl from non-muscle myosin II. Cells then attempt to
form lamellipodia at other sites, which manifest as the
multiple small protrusions observed by videomicroscopy.
This model may also explain the previous finding that
non-muscle myosin IIA inhibits cell motility [22]. The
PKCι-mediated uncoupling of Lgl from non-muscle
myosin II is a second mechanism by which PKCι can
regulate actin dynamics, as we have previously shown
that PKCι negatively regulates the expression of RhoB in
glioblastoma cells and can influence actin dynamics in
this manner [16]. These two mechanisms may act in
concert, with RhoB repression leading to destabilization
of actin filaments and Lgl/non-muscle myosin IIA
uncoupling permitting forward spreading of the
lamellipod.
Depletion or inhibition of PKCι in glioblastoma cells
caused a marked decrease in cell proliferation under
normal tissue culture conditions. This is in contrast to
findings in other cancer types, where PKCι only affected
anchorage-independent proliferation [10,25] and sug-
gests a unique role for PKCι in glioblastoma. Videomi-
croscopy showed that the impaired proliferation was
due, at least in part, to an impairment in mitosis. This
was seen when PKCι levels were depleted by stable
expression of a shRNA, or when PKCι activity was
reduced using a selective inhibitor. PKCι has not been
shown to have a role in mitosis previously. However,
Wirtz-Peitz et al. have shown that in Drosophila atypical
PKC is activated by Aurora-A kinase during mitosis and
linked this activation to the establishment of asymmetric
cell division in Drosophila neural precursors [26]. Our
work shows a more direct role for atypical PKC in mito-
sis itself. Glioblastoma cells with reduced PKCι activity
appeared to have two mitosis-related defects: (1) a
reduction in cells entering mitosis; (2) a delay or failure
to progress through mitosis normally. Aurora-A also has
roles at multiple points during mitosis [27]. This parallel
Figure 6 Effects of stable PKCι depletion on proliferation. A.
Control cells or cells expressing pshPKCιA were plated at equal
densities and viable cell numbers using trypan blue exclusion were
counted at days 1, 2, 4 and 8 after plating. Left panel, U87MG cells;
right panel, A172 cells. B. Representative example of a control and
PKCι depleted U87MG cell undergoing mitosis. Still images from
videomicroscopy are shown, with times indicated. A full video is
shown in Supplementary video S2. C. Quantitation of the number of
mitotic events observed during live cell image analysis (20 h) for
control U87MG cells or pshPKCιA expressing cells. Data are the
mean +/- SD of three independent live cell experiments for each
cell line. Inset table indicates the number of normal mitotic events
(total starting cell numbers from the three experiments in
parentheses) and the number of abnormal, delayed mitotic events
observed over the 20 h analysis for control and PKCι-depleted
U87MG cells.
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aspect to the behavior of the two kinases suggests that
PKCι may be a downstream mediator of Aurora-A in
mitosis. It will be important to determine if Aurora-A is
in fact responsible for PKCι activation in this context.
Some or all of the effects of PKCι on glioblastoma cell
proliferation could be mediated by inactivation of Lgl.
In both Drosophila and mice, mutational inactivation of
Lgl not only causes polarity defects, but also induces
uncontrolled proliferation in neural tissue [28,29]. A
role for Lgl inactivation in glioblastoma proliferation
would explain our observation that we could not isolate
a stable population of glioblastoma cells expressing a
Figure 7 Effects of PKCι pseudosubstrate inhibitor peptide on cell proliferation. A. U87MG cells were plated at equal densities and 24 h
later either control treated or treated with 20 or 50 μM PS-I and viable cell numbers were determined using trypan blue exclusion at days 0, 1,
2 and 3 after treatment. B. Representative examples comparing mitosis in control cells and cells treated with 20 μM PS-I. Still images from
videomicroscopy are shown, with times indicated on the left. A full video is shown in Supplementary S3. C. Quantitation of the number of
mitotic events observed during live cell image analysis (17 h) for U87MG cells control treated or treated with 20 μM PS-I. Data are the mean +/-
SD of three independent videomicroscopy experiments for each condition. Inset table indicates the number of normal mitotic events (total
starting cell numbers from the three experiments in parentheses) and the number of abnormal (delayed) mitotic events observed over the 17 h
analysis for control treated and PS-I treated cells.
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non-phosphorylatable version of Lgl that cannot be
inactivated by PKCι.
Our data indicate show a role for PKCι in both glio-
blastoma cell motility and mitosis. Cell movement and
mitosis are mutually exclusive events: cells arrest move-
ment and decrease their matrix attachments prior to
mitosis. It is possible that these two processes involve
separate intracellular pools of PKCι. Alternatively, a lim-
ited pool of PKCι might be co-opted away from motility
functions during mitosis, contributing to the uncoupling
of these two processes.
Conclusions
PKCι promotes glioblastoma cell invasion by coordinat-
ing lamellipod leading edge formation and has a role in
remodeling the cytoskeleton at the lamellipod leading
edge, promoting the dissociation of Lgl from non-mus-
cle myosin II. In addition PKCι is required for progres-
sion through mitosis in glioblastoma cells. The data
presented here, along with our previously published data
[16,18], show that PKCι has a role in multiple aspects of
glioblastoma cell malignancy. These include the repres-
sion of apoptosis in response to DNA damage, aberrant
proliferation and metastasis. PKCι is activated by several
different oncogenic mutations in glioblastoma, and
appears to have a non-redundant role in mediating sig-
naling downstream of these mutations. These features
suggest that PKCι is a promising target for glioblastoma
therapy that warrants further investigation.
Materials and methods
Chemicals and antibodies
Antibodies to phospho-PKCι T555 and total PKCι were
from BD Biosciences (Mississauga, ON, Canada). Mouse
anti-Flag M2 antibody and rabbit non-muscle myosin
IIA antibody were from Sigma (Oakville, ON, Canada).
Antibody to PKC consensus phosphorylation site was
from Cell Signaling Technology (Beverly, MA, USA).
Secondary antibodies Alexa-Fluor 488 chicken anti-rab-
bit and Alexa Fluor 555 goat anti-mouse were from
Invitrogen (Burlington, ON, Canada). Myristoylated aty-
pical PKC pseudosubstrate peptide was from Invitrogen
(Burlington, ON, Canada).
Cell lines
The human glioblastoma cell line U87MG was obtained
from Dr. W. Cavenee (Ludwig Institute for Cancer
Research, La Jolla, CA). A172 cells were from the Amer-
ican Type Culture Collection. Cells were cultured at 37°
C and 5% CO2 in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 100 units/ml penicillin,
100 μg/ml streptomycin, 2 mM glutamine and 10% (v/v)
of a 2:1 mixture of donor bovine serum and fetal bovine
serum. To make glioblastoma cell lines stably depleted
of PKCι, short hairpin DNA target sequences (see Addi-
tional file 1, Figure S1A) were designed and ordered
from Integrated DNA Technologies (Coralville, IA,
USA). Sense and antisense strands were annealed and
subcloned into the pSUPER.retro.puro backbone (Oli-
goEngine, Seattle, WA, USA). Replication-incompetent
retroviruses containing pshGFP, pshPKCιA or pshPKCιB
were made as described previously [30]. Cells were
gown in media containing puromycin (1 μg/mL) to
select for transductants. Control retroviruses contained
empty vector or shRNA to green fluorescent protein.
Cells were used within three weeks of selection because
of their marked growth impairment, which over time
selected for cells with reduced PKCι depletion. To make
U87MG cells expressing Flag-tagged Lgl, full-length







Figure 8 Model for the role of PKCι in lamellipod formation. An initial complex of the scaffolding protein Par6, PKCι and Lgl forms at the
plasma membrane. Lgl is in its active form and binds non-muscle myosin IIA. PKCι then phosphorylates and inactivates Lgl. Uncoupling of Lgl
from non-muscle myosin IIA then allows the actin remodeling required for lamellipod formation. In the absence of Lgl inactivation by PKCι,
lamellipod formation is aborted and cells attempt to form lamellipodia at alternate sites.
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number NM_004140) was cloned from normal human
astrocyte mRNA and subcloned into the retroviral
vector pLPCX (Clontech, Palo Alto, CA. USA). Site-
directed mutagenesis was then used to add an amino-
terminal Flag epitope. Flag-tagged Lgl was expressed in
U87MG cells using retroviral transduction followed by
puromycin selection. Transient depletion of PKCι by
RNA interference was done as described previously [18];
in some experiments an additional RNA duplex (desig-
nated C) was used that has been described previously
[17].
Western blot analysis
Western blotting was performed as described previously
[18]. After electrophoretic transfer from the gel, blots
were stained with amido black to confirm that equal
sample loading and transfer was achieved.
RT-PCR
RNA was isolated using the Qiagen’s RNeasy Plus Mini Kit
and cDNA was generated using the Qiagen Quantitect RT
Kit. PCRs were then performed using the following pri-
mers: for PUM1 (reference gene), 5’TGAGGTGTGCAC-
CATGAAC 3’ and 5’ CAGAATGTGCTTGCCATAGGG
3’; for PKCι, 5’GTCCGGGTGAAAGCCTACTAC 3’ and
5’ACGGGTCTCCTTCCTCATCT 3’; for PKCζ 5’CCAA-
GAGCCTCCAGTAGACG 3’ and 5’CCATCCATCC-
CATCGATAAC 3’.
Cell counts
Live cell number was determined using a Vi-Cell XR cell
viability analyzer with trypan blue exclusion (Beckman
Coulter Canada Inc., Mississauga, ON, Canada).
Cell motility and invasion assays
Chambers (BD Biocoat Matrigel invasion chambers, BD
Biosciences, Mississauga, ON, Canada) were rehydrated
and equilibrated for 2 h with 500 μL of serum free
DMEM medium. After 2 h, the medium in the inserts
was aspirated and inserts were placed into the wells
containing complete DMEM (10% FBS:DBS). Chambers
that were not coated with Matrigel (control inserts)
were used to measure motility. Each chamber contains a
membrane with 8 μm pores. U87MG stably expressing
PKCι short hairpin were counted and resuspended in
serum free DMEM medium at 1 × 105 cells/ml. Five
hundred μl of cell suspension (50 000 cells) were added
to each chamber. The chambers were incubated for 22
h at 37°C in a 5% CO2 atmosphere. The media was then
removed and the upper surface of the membrane was
scrubbed ten times with a cotton swab. Cells on the
lower surface of the scrubbed membranes were fixed in
10% methanol and stained with Diff-Kwik (Dade-
Behring, Newark, DE) according to the manufacturer’s
instructions. Three random fields were counted from
each chamber under the light microscope at 40×
magnification.
Time lapse videomicroscopy
Control and PKCi depleted or pseudosubstrate treated
U87MG cells were plated into a Bioptechs Delta T (But-
ler, PA) live cell imaging plate in 2 mL of complete
DMEM at a density of 103 cells to allow space for
migration. Cells were maintained at 37°C in 5% CO2 for
the duration of the videos. Videomicroscopy was done
using an inverted microscope (Ziess Axiovert 200 M)
equipped with phase-contrast microscopy using a 10×
objective. Images were acquired with a CCD camera
(AxioCam HRm) driven by Zeiss Axiovision 4.5 soft-
ware. Phase contrast images of the cells were taken at 5
min intervals for 17-20 h and compiled to generate a
time-lapse video. To quantify the migration distance per
minute, cells from three independent time-lapse imaging
experiments of each cell line were analyzed using the
Zeiss LSM image browser software. Cell nuclei were
tracked to determine migration distance and divided by
the travel time. To quantify leading edges, cells from
independent movies were assessed for the formation of
a single dominant leading edge. Once a cell generated
and formed a single leading edge it was counted. A cell
was only counted once throughout the duration of the
movie (i.e. if it changed direction and generated a new
leading edge it was not counted a second time).
Immunofluorescence and confocal microscopy
Cells were grown in 6-well TC dishes containing glass
coverslips pre-coated 0.15% Gelatin. They were washed
briefly in cold (4°C) PBS and fixed in cold 4% parafor-
madehyde for 30 minutes. Next, cells were washed in
PBS 3 times for 5 minutes each, permeablized for 10
minutes in 0.2% Triton-X 100 (diluted in PBS), and
washed in PBS again 3 times for 5 minutes each. Cells
were blocked in a solution made of 5% normal goat
serum and 5% normal chicken serum in PBS for 30
minutes at room temperature. Cells were then incubated
for 1 hour at RT with the primary antibody cocktail
which consisted of 1 ug/ml Mouse anti-Flag M2 anti-
body and 1:200 dilution of rabbit non-muscle myosin
IIA diluted in the blocking solution. Cells were washed
gently 3 times for 10 minutes each in PBS. This was fol-
lowed by a 45 minute at RT incubation with the second-
ary antibody cocktail consisting of 2 ug/ml each of Goat
anti-Mouse Alexa Fluor 555 and 2 ug/ml Chicken anti-
Rabbit Alexa-Fluor 488 diluted in the blocking solution.
Finally the cells were washed with three 10 minutes
washes in PBS, mounted on a glass slide with Prolong
Baldwin et al. Molecular Cancer 2010, 9:233
http://www.molecular-cancer.com/content/9/1/233
Page 11 of 13
gold with DAPI (Invitrogen Cat # P-36931) and allowed
to air dry overnight at RT in the dark. The following
day, coverslips were sealed with permanent mounting
media (DAKO Cat. # S3026).
Fluorescent labeling was observed using a Zeiss
Observer. Z1 microscope (63X/1.40 oil DIC M27 objec-
tive) connected to a Zeiss LSM 510 Meta confocal unit.
Alexa Fluor 555 was excited using the He-Ne 543 laser
set at 50% power and channeled through an HFT 488/
548 main dichroic filter, an NFT 545 secondary dichroic
filter and a BP 560-615 IR. Images were captured using
Zeiss’ ZEN (version 4.5) software for the confocal
microscope. AF 488 was excited with the Argon laser
set at 20% power and channeled through an HFT 488/
548 main dichroic filter and a BP 505-530 filter. DAPI
was excited using the He-Ne 405 laser set at 20% power
channeled through an HFT 405/488 main dichroic filter
and a BP 420-480 filter. Image stacks were collected
with the software Pinhole set at 1 Airy unit and a slice
interval of 0.41 um.
Statistical analysis
All results were expressed as the mean ± S.D. Statistical
analysis was performed using the Student’s t test. P <
0.05 was considered statistically significant and is indi-
cated by the symbol *.
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Additional material
Additional file 1: Figure S1. shRNA sequences and atypical PKC
isoform expression in glioblastoma cells. A. shRNA encoding
sequences ligated into the pSUPER.retro.puro shRNA expression plasmid.
B. PKCι and PKCζ mRNA expression was assessed in U87MG and A172
human glioblastoma cells by RT-PCR. The human breast cancer cell line
was used as a positive control for PKCζ expression and Pum1 mRNA was
assessed as a control to show that the input of mRNA and cDNA in each
reaction was similar.
Additional file 2: Video 1. Time lapse videomicroscopy of U87MG
cells. The video shown is of U87MG cells that were transduced with
retrovirus made with pLPCX vector expressing a shRNA to green
fluorescent protein (as a control). Time lapse videomicroscopy was
performed as described in Materials and Methods. Images were taken at
5 min intervals for 20 h. The video is a representative example of three
videos of these cells.
Additional file 3: Video 2. Time lapse videomicroscopy of U87MG
cells expressing PKCι shRNA. The video shown is of U87MG cells that
were transduced with retrovirus expressing PKCι shRNA. Other conditions
were as in Additional file 2. The video is a representative example of
three videos of these cells.
Additional file 4: Video 3. Time lapse videomicroscopy of U87MG
cells treated with PKCι pseudosubstrate inhibitor peptide. The video
shown is of U87MG cells treated with 20 μM pseudosubstrate peptide.
Other conditions were as in Additional file 2. The video is a
representative example of three videos of these cells.
Additional file 5: Figure S2. Motility, proliferation and mitosis in
A172 glioblastoma cells depleted of PKCι. A. Quantitation of A172
motility from videomicroscopy. Migration distance per minute (um/min)
was measured using Ziess LSM image browser software. Bars show the
mean +/- SD from three independent videomicroscopy experiments for
A172 cells and A172 cells stably depleted of PKCι and the mean ± range
from two independent experiments for A172 cells treated with 20 uM
pseudosubstrate inhibitor peptide (PS-I). B. Effects of transient PKCι
depletion on U87MG and A172 proliferation. U87MG cells (left panel) and
A172 cells (right panel) were either mock-transfected, transiently
transfected with a control RNA duplex, or transiently transfected with
two different duplexes targeting PKCι. Viable cell numbers were
determined using trypan blue exclusion on the indicated days after
transfection. C. Quantitation of A712 mitoses from videomicroscopy. Data
are from three independent movies for A172 and A172/pshPKCιA cells
and two independent movies for A172 cells treated with 20 uM PS-I.
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